Publications 2007
Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, Kriege M, van Geel AN, Burger CW, Eggermont AM, Meijers-Heijboer H, Klijn JG
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
Eur J Cancer. 2007 Mar;43(5):867-76
de Beukelaar JW, Gratama JW, Smitt PA, Verjans GM, Kraan J, Luider TM, Burgers PC
The impact of impurities in synthetic peptides on the outcome of T-cell stimulation assays.
Rapid Commun Mass Spectrom. 2007;21(7):1282-8
de Beukelaar JW, Sillevis Smitt PA, Hop WC, Kraan J, Hooijkaas H, Verjans GM, Gratama JW
Imbalances in circulating lymphocyte subsets in Hu antibody associated paraneoplastic neurological syndromes.
Eur J Neurol. 2007 Dec;14(12):1383-91
de Beukelaar JW, Verjans GM, van Norden Y, Milikan JC, Kraan J, Hooijkaas H, Sintnicolaas K, Gratama JW, Sillevis Smitt PA
No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies.
Cancer Immunol Immunother. 2007 Sep;56(9):1501-6
de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, Sparreboom A
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
Clin Pharmacol Ther. 2007 Jan;81(1):42-9
de Jong FA, van der Bol JM, Mathijssen RH, Loos WJ, Mathôt RA, Kitzen JJ, van den Bent MJ, Verweij J
Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity.
Cancer Biol Ther. 2007 Sep;6(9):1368-74
de Wit R, Sleijfer S, Kaye SB, Horwich A, Mead B, Sleijfer DT, Stoter G
Bleomycin and scuba diving: where is the harm?
Lancet Oncol. 2007 Nov;8(11):954-5
Echteld MA, Passchier J, Teunissen S, Claessen S, de Wit R, van der Rijt CC
Multidimensional fatigue and its correlates in hospitalised advanced cancer patients.
Eur J Cancer. 2007 Apr;43(6):1030-6
Echteld MA, van Zuylen L, Bannink M, Witkamp E, Van der Rijt CC
Changes in and correlates of individual quality of life in advanced cancer patients admitted to an academic unit for palliative care.
Palliat Med. 2007 Apr;21(3):199-205
Engels FK, de Jong FA, Mathijssen RH, Erkens JA, Herings RM, Verweij J
Medicinal cannabis in oncology.
Eur J Cancer. 2007 Dec;43(18):2638-44
Engels FK, de Jong FA, Sparreboom A, Mathot RA, Loos WJ, Kitzen JJ, de Bruijn P, Verweij J, Mathijssen RH
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
Oncologist. 2007 Mar;12(3):291-300
Engels FK, Loos WJ, Mathot RA, van Schaik RH, Verweij J
Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
Cancer Chemother Pharmacol. 2007 Sep;60(4):569-79
Engels FK, Mathot RA, Verweij J
Alternative drug formulations of docetaxel: a review.
Anticancer Drugs. 2007 Feb;18(2):95-103
Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries EG
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.
Br J Cancer. 2008 Jan 15;98(1):80-5
Hamberg P, Verweij J, Seynaeve C
Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.
Eur J Cancer. 2007 Jul;43(10):1514-28
Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Tan M, Meijers-Heijboer HE, Klijn JG, Seynaeve C
Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
Ann Surg Oncol. 2007 Dec;14(12):3335-44
Helleman J, van der Vlies D, Jansen MP, Luider TM, van der Burg ME, Stoter G, Berns EM
Serum proteomic patterns for ovarian cancer monitoring.
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95
Hinnen P, Eskens FA
Vascular disrupting agents in clinical development.
Br J Cancer. 2007 Apr 23;96(8):1159-65
Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Mol Cancer Res. 2007 Feb;5(2):195-201
Jager A, Sleijfer S, van der Rijt CC
The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator?
Eur J Cancer. 2008 Jan;44(2):175-81
Jansen MP, Sieuwerts AM, Look MP, Ritstier K, Meijer-van Gelder ME, van Staveren IL, Klijn JG, Foekens JA, Berns EM
HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
J Clin Oncol. 2007 Feb 20;25(6):662-8
Kowalski MP, Dubouix-Bourandy A, Bajmoczi M, Golan DE, Zaidi T, Coutinho-Sledge YS, Gygi MP, Gygi SP, Wiemer EA, Pier GB
Host resistance to lung infection mediated by major vault protein in epithelial cells.
Science. 2007 Jul 6;317(5834):130-2
Kriege M, Brekelmans CT, Peterse H, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG
Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer.
Breast Cancer Res Treat. 2007 May;102(3):357-63
Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, van den Ouweland A, van Geel B, Brekelmans CT, Klijn JG
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.
Breast Cancer Res Treat. 2008 Sep;111(2):303-11
Lamers CH, Langeveld SC, Groot-van Ruijven CM, Debets R, Sleijfer S, Gratama JW
Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.
Cancer Immunol Immunother. 2007 Dec;56(12):1875-83
Loos WJ, de Wit R, Freedman SJ, Van Dyck K, Gambale JJ, Li S, Murphy GM, van Noort C, de Bruijn P, Verweij J
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Cancer Chemother Pharmacol. 2007 Feb;59(3):407-12
Loos WJ, Zamboni WC, Engels FK, de Bruijn P, Lam MH, de Wit R, Verweij J, Wiemer EA
Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.
J Pharm Biomed Anal. 2007 Oct 18;45(2):288-94
Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
Oncologist. 2007 Aug;12(8):913-23
Oldenmenger WH, Echteld MA, de Wit R, Sillevis Smitt PA, Stronks DL, Stoter G, van der Rijt CC
Analgesic adherence measurement in cancer patients: comparison between electronic monitoring and diary.
J Pain Symptom Manage. 2007 Dec;34(6):639-47
Pouw NM, Westerlaken EJ, Willemsen RA, Debets R
Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes.
J Gene Med. 2007 Jul;9(7):561-70
Sebestyen Z, de Vrij J, Magnusson M, Debets R, Willemsen R
An oncolytic adenovirus redirected with a tumor-specific T-cell receptor.
Cancer Res. 2007 Dec 1;67(23):11309-16
Sieuwerts AM, Usher PA, Meijer-van Gelder ME, Timmermans M, Martens JW, Brünner N, Klijn JG, Offenberg H, Foekens JA
Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer.
Clin Chem. 2007 Jul;53(7):1280-8
Sleijfer S, Gratama JW, Sieuwerts AM, Kraan J, Martens JW, Foekens JA
Circulating tumour cell detection on its way to routine diagnostic implementation?
Eur J Cancer. 2007 Dec;43(18):2645-50
Sleijfer S, Seynaeve C, Verweij J
Gynaecological sarcomas.
Curr Opin Oncol. 2007 Sep;19(5):492-6
Sleijfer S, Wiemer E, Seynaeve C, Verweij J
Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.
Oncologist. 2007 Jun;12(6):719-26
Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
J Clin Oncol. 2007 Oct 20;25(30):4707-13
Strijbos MH, Kraan J, den Bakker MA, Lambrecht BN, Sleijfer S, Gratama JW
Cells meeting our immunophenotypic criteria of endothelial cells are large platelets.
Cytometry B Clin Cytom. 2007 Mar;72(2):86-93
Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
Oncologist. 2007 Nov;12(11):1351-60
Umar A, Luider TM, Foekens JA, Pasa-Tolić L
NanoLC-FT-ICR MS improves proteome coverage attainable for approximately 3000 laser-microdissected breast carcinoma cells.
Proteomics. 2007 Jan;7(2):323-9
van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RH, de Jonge MJ, Planting AS, Verweij J, Sparreboom A, de Jong FA
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
J Clin Oncol. 2007 Jul 1;25(19):2719-26
van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der Gaast A
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.
Br J Cancer. 2007 May 7;96(9):1348-52
van Meerten E, van der Gaast A, Looman CW, Tilanus HW, Muller K, Essink-Bot ML
Quality of life during neoadjuvant treatment and after surgery for resectable esophageal carcinoma.
Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):160-6
Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, Issels R, van Oosterom AT, Van Glabbeke M, Blay JY
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
Eur J Cancer. 2007 Apr;43(6):974-8
Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, van den Ouweland A, Meijers-Heijboer H, Schutte M
MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
Breast Cancer Res Treat. 2007 Aug;104(2):153-7
Wiemer EA
The role of microRNAs in cancer: no small matter.
Eur J Cancer. 2007 Jul;43(10):1529-44